Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 07:01 am EST
Homology Medicines, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 30.61 million compared to USD 28.23 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.62 a year ago.
For the nine months, net loss was USD 62.18 million compared to USD 98.9 million a year ago. Basic loss per share from continuing operations was USD 1.14 compared to USD 2.19 a year ago.